midazolam has been researched along with Fatty Liver, Nonalcoholic in 3 studies
Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.
midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study aimed to build a physiologically based pharmacokinetic (PBPK) model reflecting observed changes in physiological and molecular parameters relevant to drug disposition that are associated with MAFLD." | 2.82 | A Physiologically Based Pharmacokinetic Model to Predict the Impact of Metabolic Changes Associated with Metabolic Associated Fatty Liver Disease on Drug Exposure. ( Newman, EM; Rowland, A, 2022) |
| " Although some studies have explored the roles of gut microbiota and host Cyp450s in drug pharmacokinetics, few have explored their effects on pharmacokinetic variability, especially in disease states." | 1.72 | Gut microbiota and host Cyp450s co-contribute to pharmacokinetic variability in mice with non-alcoholic steatohepatitis: Effects vary from drug to drug. ( Chen, LJ; Chen, XP; Chen, Y; Guo, J; Liou, YL; Tan, ZR; Xu, Y; Zhang, SX; Zhang, W; Zhou, HH, 2022) |
| "Nonalcoholic fatty liver disease (NAFLD) is a major cause of chronic liver disease in the Western population." | 1.48 | Nonalcoholic Fatty Liver Disease and Diabetes Are Associated with Decreased CYP3A4 Protein Expression and Activity in Human Liver. ( Adusumalli, S; Akhlaghi, F; Barlock, BB; de la Monte, SM; Jamwal, R; Ogasawara, K, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, J | 1 |
| Xu, Y | 1 |
| Chen, LJ | 1 |
| Zhang, SX | 1 |
| Liou, YL | 1 |
| Chen, XP | 1 |
| Tan, ZR | 1 |
| Zhou, HH | 1 |
| Zhang, W | 1 |
| Chen, Y | 1 |
| Newman, EM | 1 |
| Rowland, A | 1 |
| Jamwal, R | 1 |
| de la Monte, SM | 1 |
| Ogasawara, K | 1 |
| Adusumalli, S | 1 |
| Barlock, BB | 1 |
| Akhlaghi, F | 1 |
1 review available for midazolam and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
A Physiologically Based Pharmacokinetic Model to Predict the Impact of Metabolic Changes Associated with Metabolic Associated Fatty Liver Disease on Drug Exposure.
Topics: Animals; Caffeine; Clozapine; Cytochrome P-450 CYP1A2; Cytochrome P-450 Enzyme System; Dextromethorp | 2022 |
2 other studies available for midazolam and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Gut microbiota and host Cyp450s co-contribute to pharmacokinetic variability in mice with non-alcoholic steatohepatitis: Effects vary from drug to drug.
Topics: Animals; Chlorzoxazone; Gastrointestinal Microbiome; Metoprolol; Mice; Midazolam; Non-alcoholic Fatt | 2022 |
Nonalcoholic Fatty Liver Disease and Diabetes Are Associated with Decreased CYP3A4 Protein Expression and Activity in Human Liver.
Topics: Cytochrome P-450 CYP3A; Diabetes Mellitus; Female; Humans; Hypnotics and Sedatives; Liver; Male; Met | 2018 |